Nutriband Inc (NTRB)

$7.15 +0.15 (2.14%)
Market Cap 86.05M
Revenue (ttm) 2.14M
Net Income (ttm) -10.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -489.72%
Debt to Equity Ratio 0.01
Volume 58,900
Avg Vol 30,722
Day's Range N/A - N/A
Shares Out 12.04M
Stochastic %K 28%
Beta 1.13
Analysts Hold
Price Target $15.00

Company Profile

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company h...

Industry: Biotechnology
Sector: Healthcare
Phone: 407 377 6695
Address:
121 South Orange Avenue, Suite 1500, Orlando, United States
NNTrader
NNTrader Oct. 24 at 5:45 PM
$NTRB what's up?
0 · Reply
NetworkNewsWire
NetworkNewsWire Oct. 24 at 3:53 PM
BioMedNewsBreaks — $NTRB Featured in Channelchek Report Highlighting AVERSA Fentanyl Progress https://ibn.fm/bClpc
0 · Reply
lastpenny101
lastpenny101 Oct. 23 at 6:51 PM
$NTRB Get the full report from Nobel Research Report: https://www.channelchek.com/company/ntrb Target Price $15.00 !!!
0 · Reply
JPCapitalInvesting
JPCapitalInvesting Oct. 23 at 4:05 PM
$NTRB $8 p/s Noble Research buy recommendation $15 target
0 · Reply
birdmanCap
birdmanCap Oct. 23 at 2:07 PM
$NTRB any update from FDA meeting? If it went well this will grab a lot of attention
0 · Reply
Channelchek
Channelchek Oct. 23 at 1:25 PM
Noble Capital Markets Research Report: Nutriband ($NTRB) – Highlights From Noble’s Virtual Conference Nutriband Is Developing Transdermal Abuse-Deterrent Technologies. Nutriband has developed abuse-deterrent technology for dermal patch drug delivery. Serguei Melnik, Interim CEO, and Irina Gram, Director, highlighted the company’s platform, known as AVERSA, and its focus on patches containing FDA-approved drugs. The presentation may be viewed here. Read more: https://www.channelchek.com/news-channel/nutriband-ntrb-highlights-from-nobles-virtual-conference
0 · Reply
hitmongreen
hitmongreen Oct. 23 at 5:29 AM
$NTRB 👀
0 · Reply
BullInvest
BullInvest Oct. 22 at 7:56 PM
$UMGP interesting moves lately. $NTRB $HYLN $SPY $XRP.X
0 · Reply
JhonHack
JhonHack Oct. 18 at 2:57 AM
$NTRB got out got out at $8.25, First time in 4 years no NTRB in my portfolio (except for the free shares that are worthless at the moment). $6.80 will suck me back in.
1 · Reply
Covode13
Covode13 Oct. 15 at 11:03 AM
$NTRB do we have a date on the approval?
0 · Reply
Latest News on NTRB
Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch

Oct 10, 2025, 7:00 AM EDT - 15 days ago

Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch

NTRBW

Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology

Oct 8, 2025, 8:30 AM EDT - 17 days ago

Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology

NTRBW

Nutriband To Present at the Noble Capital Markets' Emerging Growth Virtual Equity Conference

Oct 8, 2025, 6:30 AM EDT - 17 days ago

Nutriband To Present at the Noble Capital Markets' Emerging Growth Virtual Equity Conference

NTRBW

Nutriband Inc. to Present at the MicroCap Rodeo Conference

Sep 24, 2025, 4:05 PM EDT - 4 weeks ago

Nutriband Inc. to Present at the MicroCap Rodeo Conference

NTRBW

Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl

Sep 10, 2025, 9:15 AM EDT - 6 weeks ago

Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl

NTRBW

Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000

Sep 3, 2025, 4:01 PM EDT - 7 weeks ago

Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000

NTRBW

Nutriband Inc. to Present on the Emerging Growth Conference on August 20, 2025

Aug 18, 2025, 9:00 AM EDT - 2 months ago

Nutriband Inc. to Present on the Emerging Growth Conference on August 20, 2025

Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election

Aug 11, 2025, 5:00 AM EDT - 2 months ago

Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election

NTRBW

FDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch

Aug 8, 2025, 8:00 AM EDT - 2 months ago

FDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch

NTRBW

Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval

Jul 18, 2025, 9:15 AM EDT - 3 months ago

Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval

NTRBW

Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval

Jul 2, 2025, 8:05 AM EDT - 4 months ago

Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval

NTRBW

Nutriband Inc. added to the Russell Microcap® Index, Russell Microcap Growth® Index, Russell 3000E® Index and Russell 3000E Growth® Index

Jul 1, 2025, 7:00 AM EDT - 4 months ago

Nutriband Inc. added to the Russell Microcap® Index, Russell Microcap Growth® Index, Russell 3000E® Index and Russell 3000E Growth® Index

NTRBW

Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology

Jun 9, 2025, 7:30 AM EDT - 4 months ago

Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology

NTRBW

Nutriband CEO Publishes Letter to Shareholders

Apr 30, 2025, 7:30 AM EDT - 6 months ago

Nutriband CEO Publishes Letter to Shareholders

NTRBW

Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology

Apr 11, 2025, 7:00 AM EDT - 7 months ago

Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology

NTRBW

UPDATE – Nutriband Signs Associate Partnership with Charlotte FC

Apr 4, 2025, 5:41 PM EDT - 7 months ago

UPDATE – Nutriband Signs Associate Partnership with Charlotte FC

NTRBW

Nutriband Signs Partnership Agreement with Charlotte FC

Apr 4, 2025, 7:00 AM EDT - 7 months ago

Nutriband Signs Partnership Agreement with Charlotte FC

NTRBW

Nutriband Receives Certificate of Registration for Trademark covering Pharmaceutical and Product Research and Development.

Feb 21, 2025, 7:00 AM EST - 8 months ago

Nutriband Receives Certificate of Registration for Trademark covering Pharmaceutical and Product Research and Development.

NTRBW

Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch

Feb 13, 2025, 7:00 AM EST - 9 months ago

Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch

NTRBW

Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™

Feb 7, 2025, 8:45 AM EST - 9 months ago

Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™

NTRBW

Nutriband Issues Letter to Shareholders

Dec 31, 2024, 7:00 AM EST - 10 months ago

Nutriband Issues Letter to Shareholders

NTRBW

Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology

Dec 27, 2024, 9:25 AM EST - 10 months ago

Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology

NTRBW

Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025

Dec 4, 2024, 9:00 AM EST - 11 months ago

Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025

NTRBW

Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversa™ Abuse Deterrent Transdermal Technology

Nov 27, 2024, 7:00 AM EST - 11 months ago

Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversa™ Abuse Deterrent Transdermal Technology

NTRBW

Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application

Oct 31, 2024, 8:35 AM EDT - 1 year ago

Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application

NTRBW

Nutriband Inc Mosquito Repellent Patch Approved by Ministry of Health of Costa Rica

Oct 17, 2024, 7:00 AM EDT - 1 year ago

Nutriband Inc Mosquito Repellent Patch Approved by Ministry of Health of Costa Rica

NTRBW

Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on October 17

Oct 2, 2024, 7:00 AM EDT - 1 year ago

Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on October 17

NTRBW

Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology

Sep 24, 2024, 7:00 AM EDT - 1 year ago

Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology

NTRBW

Nutriband Licenses Bitrex(R) Brand Aversive Agent for Its Lead Product - Aversa(TM) Fentanyl Transdermal Patch

Sep 20, 2024, 6:50 AM EDT - 1 year ago

Nutriband Licenses Bitrex(R) Brand Aversive Agent for Its Lead Product - Aversa(TM) Fentanyl Transdermal Patch

NTRBW

Nutriband Inc. Authorizes $1M Share Buyback Program

Sep 16, 2024, 4:00 PM EDT - 1 year ago

Nutriband Inc. Authorizes $1M Share Buyback Program

NTRBW

Nutriband Inc. Quarterly Report Highlights Strong Cash Position, and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025

Sep 4, 2024, 7:00 AM EDT - 1 year ago

Nutriband Inc. Quarterly Report Highlights Strong Cash Position, and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025

NTRBW

Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on July 25

Jul 19, 2024, 7:00 AM EDT - 1 year ago

Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on July 25

NTRBW

Nutriband Receives Notice of Allowance for U.S. Trademark Covering AVERSA(TM) Abuse Deterrent Technology

Jul 15, 2024, 7:00 AM EDT - 1 year ago

Nutriband Receives Notice of Allowance for U.S. Trademark Covering AVERSA(TM) Abuse Deterrent Technology

NTRBW

Nutriband Provides Product Development Update for Its Lead Product Aversa Fentanyl

Jun 20, 2024, 7:00 AM EDT - 1 year ago

Nutriband Provides Product Development Update for Its Lead Product Aversa Fentanyl

NTRBW

Nutriband Inc. Quarterly Report Emphasizes Focus on Kinesiology Tape Output as Q1 Sports Tape Revenues Increase 219% Year Over Year

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Nutriband Inc. Quarterly Report Emphasizes Focus on Kinesiology Tape Output as Q1 Sports Tape Revenues Increase 219% Year Over Year

NTRBW

Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of Directors

May 16, 2024, 7:00 AM EDT - 1 year ago

Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of Directors

NTRBW

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

May 10, 2024, 9:00 AM EDT - 1 year ago

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

CANF

Nutriband Inc. Signs Exclusive Supplier Agreement with Major Sports Brand Licensee Fit for Life Group

Apr 23, 2024, 7:00 AM EDT - 1 year ago

Nutriband Inc. Signs Exclusive Supplier Agreement with Major Sports Brand Licensee Fit for Life Group

NTRBW

Nutriband Inc. Announces $8.4M Private Placement

Apr 19, 2024, 7:00 AM EDT - 1 year ago

Nutriband Inc. Announces $8.4M Private Placement

NTRBW

Nutriband Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented at 2024 American Academy of Pain Medicine Annual Meeting

Mar 25, 2024, 7:00 AM EDT - 1 year ago

Nutriband Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented at 2024 American Academy of Pain Medicine Annual Meeting

NTRBW

Prescription Transdermal Patch Abuse and Accidental Pediatric Exposure Remains a Serious Problem in the United States - Surveillance Data to Be Presented at 2024 American Academy of Pain Medicine Annual Meeting

Mar 4, 2024, 7:00 AM EST - 1 year ago

Prescription Transdermal Patch Abuse and Accidental Pediatric Exposure Remains a Serious Problem in the United States - Surveillance Data to Be Presented at 2024 American Academy of Pain Medicine Annual Meeting

NTRBW

Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st

Jan 29, 2024, 7:00 AM EST - 1 year ago

Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st

NTRBW

Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling

Nov 28, 2023, 7:00 AM EST - 2 years ago

Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling

NTRBW

Nutriband Inc. Signs Supplier Agreement With KT Tape, the World Leader in Kinesiology Tape

Nov 8, 2023, 7:00 AM EST - 2 years ago

Nutriband Inc. Signs Supplier Agreement With KT Tape, the World Leader in Kinesiology Tape

NTRBW

Nutriband's Aversa(TM) Buprenoprhine May Reach Peak Annual Sales of $70-130 Million Based on Market Assessment by Leading Healthcare Consulting Firm

Oct 11, 2023, 7:42 AM EDT - 2 years ago

Nutriband's Aversa(TM) Buprenoprhine May Reach Peak Annual Sales of $70-130 Million Based on Market Assessment by Leading Healthcare Consulting Firm

NTRBW

Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology

Sep 20, 2023, 7:30 AM EDT - 2 years ago

Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology

NTRBW

Nutriband Inc. Receives Five Nominations in the Pharma Industry Awards 2023

Sep 12, 2023, 7:00 AM EDT - 2 years ago

Nutriband Inc. Receives Five Nominations in the Pharma Industry Awards 2023

Nutriband Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

Sep 11, 2023, 7:00 AM EDT - 2 years ago

Nutriband Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

NTRBW

Nutriband Inc. Announces Donovan McNabb as AI Tape Brand Ambassador

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Nutriband Inc. Announces Donovan McNabb as AI Tape Brand Ambassador

NTRBW

Nutriband Inc. Launches AI Tape Brand Direct-to Consumer Offerings

Jul 27, 2023, 8:30 AM EDT - 2 years ago

Nutriband Inc. Launches AI Tape Brand Direct-to Consumer Offerings

NTRBW

NNTrader
NNTrader Oct. 24 at 5:45 PM
$NTRB what's up?
0 · Reply
NetworkNewsWire
NetworkNewsWire Oct. 24 at 3:53 PM
BioMedNewsBreaks — $NTRB Featured in Channelchek Report Highlighting AVERSA Fentanyl Progress https://ibn.fm/bClpc
0 · Reply
lastpenny101
lastpenny101 Oct. 23 at 6:51 PM
$NTRB Get the full report from Nobel Research Report: https://www.channelchek.com/company/ntrb Target Price $15.00 !!!
0 · Reply
JPCapitalInvesting
JPCapitalInvesting Oct. 23 at 4:05 PM
$NTRB $8 p/s Noble Research buy recommendation $15 target
0 · Reply
birdmanCap
birdmanCap Oct. 23 at 2:07 PM
$NTRB any update from FDA meeting? If it went well this will grab a lot of attention
0 · Reply
Channelchek
Channelchek Oct. 23 at 1:25 PM
Noble Capital Markets Research Report: Nutriband ($NTRB) – Highlights From Noble’s Virtual Conference Nutriband Is Developing Transdermal Abuse-Deterrent Technologies. Nutriband has developed abuse-deterrent technology for dermal patch drug delivery. Serguei Melnik, Interim CEO, and Irina Gram, Director, highlighted the company’s platform, known as AVERSA, and its focus on patches containing FDA-approved drugs. The presentation may be viewed here. Read more: https://www.channelchek.com/news-channel/nutriband-ntrb-highlights-from-nobles-virtual-conference
0 · Reply
hitmongreen
hitmongreen Oct. 23 at 5:29 AM
$NTRB 👀
0 · Reply
BullInvest
BullInvest Oct. 22 at 7:56 PM
$UMGP interesting moves lately. $NTRB $HYLN $SPY $XRP.X
0 · Reply
JhonHack
JhonHack Oct. 18 at 2:57 AM
$NTRB got out got out at $8.25, First time in 4 years no NTRB in my portfolio (except for the free shares that are worthless at the moment). $6.80 will suck me back in.
1 · Reply
Covode13
Covode13 Oct. 15 at 11:03 AM
$NTRB do we have a date on the approval?
0 · Reply
NetworkNewsWire
NetworkNewsWire Oct. 10 at 6:17 PM
BioMedNewsBreaks – $NTRB Partners with Brand Institute to Develop Global Brand Identity for AVERSA FENTANYL https://ibn.fm/v3G9Y
0 · Reply
NNTrader
NNTrader Oct. 10 at 5:27 PM
$NTRB added 20 shares
0 · Reply
NNTrader
NNTrader Oct. 10 at 2:38 PM
$NTRB any idea why did it drop?
3 · Reply
lastpenny101
lastpenny101 Oct. 10 at 1:11 PM
$NTRB https://finance.yahoo.com/news/nutriband-signs-agreement-brand-institute-110000976.html
0 · Reply
lastpenny101
lastpenny101 Oct. 10 at 1:10 PM
$NTRB https://www.youtube.com/shorts/hRFu6MFq1Gw
0 · Reply
Covode13
Covode13 Oct. 8 at 9:10 PM
$NTRB
0 · Reply
NetworkNewsWire
NetworkNewsWire Oct. 8 at 5:10 PM
BioMedNewsBreaks – $NTRB to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference https://ibn.fm/mYatV
0 · Reply
NNTrader
NNTrader Oct. 8 at 3:47 PM
$NTRB good news are coming
0 · Reply
lastpenny101
lastpenny101 Oct. 8 at 3:25 PM
$NTRB https://finance.yahoo.com/news/nutriband-files-provisional-patent-application-123000745.html
0 · Reply
Covode13
Covode13 Oct. 8 at 3:14 PM
$NTRB $CRDL
0 · Reply
yl_trader
yl_trader Oct. 6 at 3:15 PM
$NTRB in
0 · Reply
TraderMadness
TraderMadness Oct. 6 at 3:00 PM
$NTRB issued $15 target https://youtube.com/shorts/hRFu6MFq1Gw?feature=share
0 · Reply